<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00208403</url>
  </required_header>
  <id_info>
    <org_study_id>CT02/08</org_study_id>
    <nct_id>NCT00208403</nct_id>
  </id_info>
  <brief_title>A Randomised Single Centre Study to Compare the Long-term Performance of Acryloc™ and Palacos® R Bone Cements in Primary Total Hip Replacement</brief_title>
  <official_title>Randomised, Prospective, RSA, PMS Study Comparing Acryloc™ &amp; Palacos R in Primary Total Hip Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DePuy International</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>DePuy International</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to monitor the stability of a total hip replacement within the&#xD;
      thigh bone when used in artificial hip joints implanted with two different bone cements,&#xD;
      Acryloc™ and Palacos® R, in the treatment of patients with hip joint disease requiring a&#xD;
      total hip replacement. Patients who enter the study will be randomly allocated to Acryloc™ or&#xD;
      Palacos® R and will be evaluated at regular intervals following hip surgery using patient,&#xD;
      clinical, x-ray assessments and special x-rays which allow the stability of the hip implant&#xD;
      to be determined&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>October 2002</start_date>
  <completion_date type="Actual">October 2005</completion_date>
  <primary_completion_date type="Actual">October 2005</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Distal migration of the femoral prosthesis from the time of implantation to the 2 year follow-up assessment</measure>
    <time_frame>2 Year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Annual posterior (AP) and medio-lateral (ML) RSA translations</measure>
    <time_frame>Annually</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Merle D'Aubigne score</measure>
    <time_frame>Annually</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographic analysis</measure>
    <time_frame>Annually</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier Survivorship - Revision of any component for any reason</measure>
    <time_frame>Throughout Study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Osteoarthritis</condition>
  <condition>Post-traumatic Arthritis</condition>
  <condition>Avascular Necrosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Acryloc™ GHV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Palacos R</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Acryloc™ GHV</intervention_name>
    <description>A high viscosity bone cement for use in total hip replacement</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Palacos R</intervention_name>
    <description>A high viscosity bone cement for use in total hip replacement</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        i) Male or female subjects, aged 60 to 75 years (inclusive), and with a weight of less than&#xD;
        100kg.&#xD;
&#xD;
        ii) Subjects who are able to give voluntary, written informed consent to participate in&#xD;
        this investigation and from whom consent has been obtained.&#xD;
&#xD;
        iii) Subjects who, in the opinion of the Investigator, are able to understand this&#xD;
        investigation, co-operate with the investigational procedures and are willing to return to&#xD;
        the hospital for all the required post-operative follow-ups.&#xD;
&#xD;
        iv) Subjects with non-inflammatory arthritis of the hip.&#xD;
&#xD;
        v) Subjects who require a primary total hip arthroplasty and are treated at the&#xD;
        arthroplasty section of the orthopaedics department at the Investigational Centre.&#xD;
&#xD;
        vi) Subjects who are considered suitable for a cemented femoral stem and cemented&#xD;
        acetabular component.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        i) Subjects who, in the opinion of the Investigator, have an existing condition such as&#xD;
        malignancy, severe osteoporosis, disabling musculo-skeletal problems (other than in the&#xD;
        hips) or any other condition that would compromise their participation and follow-up in&#xD;
        this study.&#xD;
&#xD;
        ii) Women who are pregnant.&#xD;
&#xD;
        iii) Subjects who are known drug or alcohol abusers or with psychological disorders that&#xD;
        could effect follow-up care or treatment outcomes.&#xD;
&#xD;
        iv) Subjects who have participated in a clinical study with an investigational product in&#xD;
        the last 6 month(s).&#xD;
&#xD;
        v) Subjects who are currently involved in any injury litigation claims.&#xD;
&#xD;
        vi) Subjects undergoing corticosteroid treatment.&#xD;
&#xD;
        vii) Subjects with any condition for whom the use of conventional bone cement is&#xD;
        contra-indicated.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospital of Trondheim</name>
      <address>
        <city>Trondheim</city>
        <state>Sor-Trondelag</state>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <last_update_submitted>March 27, 2017</last_update_submitted>
  <last_update_submitted_qc>March 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hip</keyword>
  <keyword>Cement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Necrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polymethyl Methacrylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

